Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.

The exception was a borderline significant interaction test observed for hypoglycemia across 4 eGFR subgroups ( P heterogeneity = 0.06), which persisted when assessed using eGFR as a continuous variable ( P heterogeneity = 0.004), although participants were more likely to be receiving concomitant insulin therapy as kidney function declined.

also in 11,409 other papers